Posttranslational Processing of Nuclear Lamins

Enzymes

Volumn 29, Issue , 2011, Pages 21-41

  Davies, Brandon S J ^a   Coffinier, Catherine ^a   Yang, Shao H ^a   Jung, Hea Jin ^a   Fong, Loren G ^a   Young, Stephen G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiomyopathy; Nuclear lamina; Prelamin A; Progeria; Protein farnesylation; Restrictive dermopathy

Indexed keywords

EID: 79960212131     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381339-8.00003-2     Document Type: Chapter

References (95)

1. Burke B., Stewart C.L. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol 2002, 3:575-585.
2. Muchir A., Worman H.J. The nuclear envelope and human disease. Physiology (Bethesda) 2004, 19:309-314.
3. Worman H.J., Bonne G. " Laminopathies": a wide spectrum of human diseases. Exp Cell Res 2007, 313:2121-2133.
4. Mounkes L.C., Burke B., Stewart C.L. The A-Type lamins: nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc Med 2001, 11:280-285.
5. Wilson K.L. The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol 2000, 10:125-129.
6. Fisher D.Z., Chaudhary N., Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci USA 1986, 83:6450-6454.
7. Lin F., Worman H.J. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 1993, 268:16321-16326.
8. Casey P.J. Biochemistry of protein prenylation. J Lipid Res 1992, 33:1731-1740.
9. Casey P.J., Seabra M.C. Protein prenyltransferases. J Biol Chem 1996, 271:5289-5292.
10. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
11. Schafer W.R., Rine J. Protein prenylation: genes, enzymes, targets, and functions. Annu Rev Genet 1992, 26:209-237.
12. Kim E., et al. Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem 1999, 274:8383-8390.
13. Maske C.P., Hollinshead M.S., Higbee N.C., Bergo M.O., Young S.G., Vaux D.J. A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation. J Cell Biol 2003, 162:1223-1232.
14. Otto J.C., Kim E., Young S.G., Casey P.J. Cloning and characterization of a mammalian prenyl protein-specific protease. J Biol Chem 1999, 274:8379-8382.
15. Bergo M.O., et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci USA 2002, 99:13049-13054.
16. Corrigan D.P., et al. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J 2005, 387:129-138.
17. Clarke S., Vogel J.P., Deschenes R.J., Stock J. Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc Natl Acad Sci USA 1988, 85:4643-4647.
18. Dai Q., et al. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem 1998, 273:15030-15034.
19. Bergo M.O., et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem 2001, 276:5841-5845.
20. Bergo M.O., Leung G.K., Ambroziak P., Otto J.C., Casey P.J., Young S.G. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J Biol Chem 2000, 275:17605-17610.
21. Beck L.A., Hosick T.J., Sinensky M. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J Cell Biol 1988, 107:1307-1316.
22. Wolda S.L., Glomset J.A. Evidence for modification of lamin B by a product of mevalonic acid. J Biol Chem 1988, 263:5997-6000.
23. Broers J.L., et al. A- and B-type lamins are differentially expressed in normal human tissues. Histochem Cell Biol 1997, 107:505-517.
24. Rober R.A., Sauter H., Weber K., Osborn M. Cells of the cellular immune and hemopoietic system of the mouse lack lamins A/C: distinction versus other somatic cells. J Cell Sci 1990, 95(Pt 4):587-598.
25. Rober R.A., Weber K., Osborn M. Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 1989, 105:365-378.
26. Stewart C., Burke B. Teratocarcinoma stem cells and early mouse embryos contain only a single major lamin polypeptide closely resembling lamin B. Cell 1987, 51:383-392.
27. Padiath Q.S., et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 2006, 38:1114-1123.
28. Vergnes L., PÇterfy M., Bergo M.O., Young S.G., Reue K. Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci USA 2004, 101:10428-10433.
29. Izumi M., Vaughan O.A., Hutchison C.J., Gilbert D.M. Head and/or CaaX domain deletions of lamin proteins disrupt preformed lamin A and C but not lamin B structure in mammalian cells. Mol Biol Cell 2000, 11:4323-4337.
30. Krohne G., Waizenegger I., Hoger T.H. The conserved carboxy-terminal cysteine of nuclear lamins is essential for lamin association with the nuclear envelope. J Cell Biol 1989, 109:2003-2011.
31. Dalton M.B., et al. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization. Cancer Res 1995, 55:3295-3304.
32. Vorburger K., Lehner C.F., Kitten G.T., Eppenberger H.M., Nigg E.A. A second higher vertebrate B-type lamin. cDNA sequence determination and in vitro processing of chicken lamin B2. J Mol Biol 1989, 208:405-415.
33. Hoger T.H., Zatloukal K., Waizenegger I., Krohne G. Characterization of a second highly conserved B-type lamin present in cells previously thought to contain only a single B-type lamin. Chromosoma 1990, 99:379-390.
34. Coffinier C., et al. Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc Natl Acad Sci USA 2010, 107:5076-5081.
35. Solecki D.J., Govek E.E., Tomoda T., Hatten M.E. Neuronal polarity in CNS development. Genes Dev 2006, 20:2639-2647.
36. Vallee R.B., Tsai J.W. The cellular roles of the lissencephaly gene LIS1, and what they tell us about brain development. Genes Dev 2006, 20:1384-1393.
37. Wynshaw-Boris A., Gambello M.J. LIS1 and dynein motor function in neuronal migration and development. Genes Dev 2001, 15:639-651.
38. Ayala R., Shu T., Tsai L.H. Trekking across the brain: the journey of neuronal migration. Cell 2007, 128:29-43.
39. Gleeson J.G., Walsh C.A. Neuronal migration disorders: from genetic diseases to developmental mechanisms. Trends Neurosci 2000, 23:352-359.
40. Wynshaw-Boris A. Lissencephaly and LIS1: insights into the molecular mechanisms of neuronal migration and development. Clin Genet 2007, 72:296-304.
41. Kilic F., Johnson D.A., Sinensky M. Subcellular localization and partial purification of prelamin A endoprotease: an enzyme which catalyzes the conversion of farnesylated prelamin A to mature lamin A. FEBS Lett 1999, 450:61-65.
42. Fong L.G., et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci USA 2004, 101:18111-18116.
43. Pendas A.M., et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 2002, 31:94-99.
44. Sinensky M., Fantle K., Trujillo M., McLain T., Kupfer A., Dalton M. The processing pathway of prelamin A. J Cell Sci 1994, 107(Pt 1):61-67.
45. Vaughan O.A., et al. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. J Cell Sci 2001, 114:2577-2590.
46. Fong L.G., et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 2006, 116:743-752.
47. Yang S.H., et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 2005, 102:10291-10296.
48. Yang S.H., et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 2006, 116:2115-2121.
49. Yang S.H., Andres D.A., Spielmann H.P., Young S.G., Fong L.G. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest 2008, 118:3291-3300.
50. Yang S.H., et al. Absence of progeria-like disease phenotypes in knock-in mice expressing a nonfarnesylated version of progerin. Hum Mol Genet 2011, 20:436-444.
51. Davies B.S., et al. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 2010, 19:2682-2694.
52. Coffinier C., et al. Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem 2010, 285:20818-20826.
53. Davies B.S., et al. Investigating the purpose of prelamin A processing. Nucleus 2011, 2:4-9.
54. Sullivan T., et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 1999, 147:913-920.
55. Lammerding J., et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004, 113:370-378.
56. Wolf C.M., et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol 2008, 44:293-303.
57. Bonne G., et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999, 21:285-288.
58. Sebillon P., et al. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 2003, 40:560-567.
59. van Engelen B.G., Muchir A., Hutchison C.J., van der Kooi A.J., Bonne G., Lammens M. The lethal phenotype of a homozygous nonsense mutation in the lamin A/C gene. Neurology 2005, 64:374-376.
60. Leung G.K., et al. Biochemical studies of Zmpste24-deficient mice. J Biol Chem 2001, 276:29051-29058.
61. Toth J.I., et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 2005, 102:12873-12878.
62. Coffinier C., et al. A potent HIV protease inhibitor, Darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem 2008, 283:9797-9804.
63. Moulson C.L., Go G., van der Wal A.C., Smitt J.H., van Hagen J.M., Miner J.H. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol 2005, 125:913-919.
64. Navarro C.L., et al. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet 2005, 14:1503-1513.
65. Batstone M.D., Macleod A.W.G. Oral and maxillofacial surgical considerations for a case of Hutchinson-Gilford progeria. Int J Paediatr Dent 2002, 12:429-432.
66. DeBusk F.L. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr 1972, 80:697-724.
67. Eriksson M., et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003, 423:293-298.
68. Faivre L., Kien P.K.V., Madinier-Chappat N., Nivelon-Chevallier A., Beer F., LeMerrer M. Can Hutchinson-Gilford progeria syndrome be a neonatal condition?. Am J Hum Genet 1999, 87:450-452.
69. Fernandez-Palazzi F., McLaren A.T., Slowie D.F. Report on a case of Hutchinson-Gilford progeria, with special reference to orthopedic problems. Eur J Pediatr Surg 1992, 2:378-382.
70. Khalifa M.M. Hutchinson-Gilford progeria syndrome: report of a Libyan family and evidence of autosomal recessive inheritance. Clin Genet 1989, 35:125-132.
71. Rodríguez J.I., Perez-Alonso P., Funes R., Perez-Rodríguez J. Lethal neonatal Hutchinson-Gilford progeria syndrome. Am J Med Genet 1999, 82:242-248.
72. Dechat T., et al. Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci USA 2007, 104:4955-4960.
73. Goldman R.D., et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004, 101:8963-8968.
74. Yang S.H., Qiao X., Farber E., Chang S.Y., Fong L.G., Young S.G. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford Progeria Syndrome allele. J Biol Chem 2008, 283:7094-7099.
75. Capell B.C., et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005, 102:12879-12884.
76. Glynn M.W., Glover T.W. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005, 14:2959-2969.
77. Mallampalli M.P., Huyer G., Bendale P., Gelb M.H., Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005, 102:14416-14421.
78. Fong L.G., et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006, 311:1621-1623.
79. Yang S.H., Chang S.Y., Andres D.A., Spielmann H.P., Young S.G., Fong L.G. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J Lipid Res 2010, 51:400-405.
80. Yang S.H., Qiao X., Fong L.G., Young S.G. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta 2008, 1781:36-39.
81. Muchir A., et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 2000, 9:1453-1459.
82. Vytopil M., et al. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet 2003, 40:e132.
83. Arimura T., et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 2005, 14:155-169.
84. Mounkes L.C., Kozlov S.V., Rottman J.N., Stewart C.L. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 2005, 14:2167-2180.
85. Whyte D.B., et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997, 272:14459-14464.
86. Rusinol A.E., Sinensky M.S. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 2006, 119:3265-3272.
87. Lee R., et al. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet 2010, 19:1603-1617.
88. Varela I., et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008, 14:767-772.
89. Davies B.S., et al. Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. J Lipid Res 2009, 50:126-134.
90. Liu M., et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci USA 2010, 107:6471-6476.
91. Beck L.A., Hosick T.J., Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990, 110:1489-1499.
92. Lutz R.J., Trujillo M.A., Denham K.S., Wenger L., Sinensky M. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci USA 1992, 89:3000-3004.
93. Vorburger K., Kitten G.T., Nigg E.A. Modification of nuclear lamin proteins by a mevalonic acid derivative occurs in reticulocyte lysates and requires the cysteine residue of the C-terminal CXXM motif. EMBO J 1989, 8:4007-4013.
94. Weber K., Plessmann U., Traub P. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett 1989, 257:411-414.
95. Hennekes H., Nigg E.A. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci 1994, 107(Pt 4):1019-1029.